Illumisoft Announces Plans with CHAIR for Canadian Hospital Research Program to Evaluate SaniLume

Illumisoft's hospital UV study hinges on uncommitted funding and no signed orders.

What the company is saying

Illumisoft Lighting Corp. is announcing a collaboration with the Coalition for Community & Healthcare Acquired Infection Reduction (CHAIR) to plan a Canadian hospital research program evaluating its SaniLume upper-air UV disinfection device. The company frames this as a step toward validating SaniLume's real-world impact, emphasizing that the program is designed to measure airborne pathogen reduction, surface contamination, and respiratory viral illness transmission in clinical settings. The announcement stresses that Illumisoft expects—but has not yet secured—an agreement with CHAIR to provide SaniLume units, and that CHAIR's letters of intent with hospital authorities are non-binding. CEO Ehsan Agahi highlights the goal of providing hospitals with a continuous air disinfection solution, while CHAIR's Barry Hunt positions the research as a necessary test for upper-air UV in occupied hospital spaces. The company is explicit that it has not received purchase orders, is not a party to the letters of intent, and does not control the program's timing or funding. Illumisoft also announces its shares are now DTC eligible in the United States and have recently begun trading on the OTCQB under the symbol FUVCF. The tone is measured, with repeated caveats about the conditional and early-stage nature of the initiative.

What the data suggests

The announcement discloses that the planned hospital research program comprises 13 linked studies, with an intended start in November 2026, contingent on securing funding. No funding has been obtained, and no definitive agreements or purchase orders exist between Illumisoft and CHAIR or any hospital authority. SaniLume's only quantified performance data comes from University of Leeds chamber testing, showing a 97% to 99.7% reduction in airborne concentrations of test organisms, but the company acknowledges these results may not translate to clinical settings. The number of SaniLume units, pricing, and commercial terms for the proposed research have not been determined. Illumisoft's shares have recently become DTC eligible and began trading on the OTCQB. There are no disclosed financial figures, revenue, or projections, and the company is transparent about the lack of commercial traction or secured contracts at this stage. The evidence supports that the project is at a pre-commercial, pre-funding planning phase, with all material outcomes dependent on future events.

Analysis

The announcement is measured in tone and transparent about the conditional and early-stage nature of the hospital research program. While there are forward-looking statements regarding the intention to enter into agreements and the planned start of studies in November 2026, the company clearly discloses that funding is not secured, no purchase orders exist, and no definitive agreements have been signed. The technical performance data for SaniLume is limited to prior laboratory testing, with explicit caveats that these results do not guarantee clinical performance. The DTC eligibility and OTCQB listing are factual, routine disclosures. There is no evidence of exaggerated claims or narrative inflation; the company repeatedly emphasizes the uncertainty and lack of control over the program's timing and outcome. No large capital outlay or immediate financial impact is disclosed.

Risk flags

• ●The entire research program is contingent on external funding, which has not been secured. If funding is not obtained, none of the planned studies or installations will proceed, eliminating any near-term commercial opportunity.
• ●Illumisoft is not a party to the non-binding letters of intent with hospital authorities and has no control over the program's execution, timing, or design. This lack of control increases the risk that the program may be delayed, altered, or cancelled without recourse.
• ●No purchase orders, definitive agreements, or commercial terms have been finalized for SaniLume units. The absence of committed sales or pricing means there is no visibility on potential revenue or margins from this initiative.
• ●Laboratory test results (97%–99.7% airborne pathogen reduction) may not translate to clinical effectiveness. If real-world studies fail to replicate these results, market adoption could be limited or negative.
• ●The company's announcement of DTC eligibility and OTCQB trading may improve share liquidity but does not address the underlying commercial or operational risks of the core business.

Bottom line

Illumisoft is publicizing a potential hospital research program for its SaniLume UV device, but all progress depends on third-party funding that is not yet in place. There are no signed agreements, purchase orders, or committed sales, and the company has no direct control over the program's timing or execution. While SaniLume has shown strong laboratory results, these have not been validated in clinical environments, and the company is explicit about this gap. The announcement of DTC eligibility and OTCQB trading is routine and does not offset the lack of commercial traction. For investors, this update signals a possible future opportunity but offers no near-term revenue or contract catalysts. The single most important takeaway is that Illumisoft's hospital research ambitions remain speculative until funding and binding agreements are secured.

Announcement summary

(TSXV:UVC, OTCQB:FUVCF) Illumisoft Lighting Corp. announced a collaboration with the Coalition for Community & Healthcare Acquired Infection Reduction (CHAIR), a Canadian not-for-profit coalition, to develop plans for a Canadian hospital research program evaluating the Company's SaniLume upper-air ultraviolet (UV) disinfection device. Illumisoft expects to enter into an agreement with CHAIR to provide SaniLume units for the program. CHAIR has entered into non-binding letters of intent with Shared Health and Winnipeg's Health Sciences Centre in Manitoba, and with the Provincial Health Services Authority in British Columbia, for planned facility-wide installations of SaniLume as part of the program. The program is planned to include 13 linked studies, beginning with two studies in partnership with the University of Waterloo: a bioaerosol chamber study comparing hospital ventilation rates with and without upper-air UV, and a computational fluid dynamics study of air movement in clinical spaces. The program is designed to measure the effect of SaniLume on airborne pathogens, surface contamination, and transmission of respiratory viral illness. CHAIR intends to begin the studies in November 2026, subject to funding, which has not yet been secured. Under the proposed agreement, Illumisoft would provide SaniLume units for the planned installations and studies, but the number of units, pricing, and other terms have not yet been finalized. Illumisoft is not a party to the letters of intent, has not received any purchase orders in connection with the program, and does not control the program or its timing. There is no assurance that the program will be funded, that the planned installations or studies will proceed, or that Illumisoft will enter into a definitive agreement with CHAIR on the terms described or at all. CHAIR does not receive any compensation from Illumisoft and does not hold any interest in Illumisoft. SaniLume is a Health Canada-licensed, fan-assisted upper-air UV device manufactured by Illumisoft in Ottawa. In chamber testing at the University of Leeds, reported in August 2022 and commissioned and funded by Illumisoft, SaniLume reduced airborne concentrations of the test organisms (Staphylococcus aureus, Pseudomonas aeruginosa, and the virus surrogate Phi-6 bacteriophage) by between 97% and 99.7%, depending on organism and device setting. Laboratory results do not establish performance in clinical settings, which the program is intended to evaluate. Ehsan Agahi, CEO of Illumisoft, stated that the goal is to give hospitals a practical way to continuously disinfect the air while patients and staff remain in the room, and that the proposed research is intended to help hospitals assess SaniLume's performance in clinical settings and make informed decisions about potential broader adoption. Barry Hunt, Co-Founder and Executive Director of CHAIR, stated that treating the air while patients and staff are in the room is the next step, and the program is designed to test whether upper-air UV can do that in real hospitals, with studies intended to begin in November 2026, subject to funding. Illumisoft also announced that its common shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (DTC). DTC eligibility is expected to simplify the process of trading and enhance liquidity of Illumisoft's shares in the United States. The Company's shares recently began trading on the OTCQB Venture Market under the ticker symbol FUVCF. The Company's common shares also trade on the TSX Venture Exchange under the symbol UVC.

Disagree with this article?